| Code | Description | Claims | Beneficiaries | Total Paid |
| 36415 |
Collection of venous blood by venipuncture |
23,590 |
18,415 |
$1.77M |
| 80053 |
Comprehensive metabolic panel |
20,769 |
18,848 |
$867K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
20,172 |
19,183 |
$724K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,861 |
4,742 |
$517K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
4,933 |
4,747 |
$412K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
9,540 |
7,905 |
$272K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,911 |
2,791 |
$256K |
| 86850 |
|
1,843 |
1,721 |
$253K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
6,227 |
3,927 |
$237K |
| 81025 |
|
7,999 |
7,531 |
$237K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
7,588 |
6,934 |
$234K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
6,462 |
5,641 |
$231K |
| 76830 |
Ultrasound, transvaginal |
737 |
722 |
$220K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,140 |
1,125 |
$140K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
468 |
289 |
$134K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,211 |
2,115 |
$125K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
7,997 |
7,553 |
$109K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
5,011 |
4,541 |
$108K |
| 81001 |
|
11,084 |
10,319 |
$102K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
12,982 |
12,195 |
$97K |
| 87081 |
|
2,594 |
2,558 |
$94K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
111 |
109 |
$92K |
| 71046 |
Radiologic examination, chest; 2 views |
5,449 |
5,272 |
$90K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
618 |
591 |
$88K |
| 73610 |
|
1,475 |
1,412 |
$84K |
| 87070 |
|
1,035 |
970 |
$83K |
| 87077 |
|
3,639 |
3,457 |
$81K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
2,001 |
1,923 |
$78K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,388 |
1,362 |
$72K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
3,023 |
2,747 |
$71K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
425 |
411 |
$71K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,055 |
2,887 |
$70K |
| 73130 |
|
1,016 |
981 |
$66K |
| 73630 |
|
1,678 |
1,605 |
$64K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
854 |
829 |
$63K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
3,420 |
3,290 |
$61K |
| 81003 |
|
3,203 |
3,065 |
$53K |
| 73110 |
|
838 |
814 |
$50K |
| 73564 |
|
1,467 |
1,377 |
$49K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
11,364 |
10,502 |
$42K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,162 |
1,140 |
$41K |
| 82565 |
|
309 |
262 |
$36K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
960 |
940 |
$36K |
| 71045 |
Radiologic examination, chest; single view |
5,517 |
5,108 |
$36K |
| 86900 |
|
2,106 |
1,946 |
$35K |
| 73030 |
|
993 |
960 |
$32K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
531 |
520 |
$31K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,268 |
973 |
$31K |
| 93971 |
|
241 |
238 |
$27K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,047 |
1,033 |
$27K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
28,201 |
24,071 |
$26K |
| 84702 |
|
2,068 |
1,684 |
$25K |
| 71250 |
|
126 |
125 |
$23K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
1,962 |
1,874 |
$23K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
453 |
446 |
$22K |
| 72100 |
|
979 |
964 |
$22K |
| 87210 |
|
819 |
801 |
$21K |
| 74018 |
|
657 |
636 |
$19K |
| 97597 |
|
503 |
260 |
$19K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
201 |
201 |
$18K |
| 76642 |
|
524 |
449 |
$16K |
| 80061 |
Lipid panel |
3,759 |
3,717 |
$13K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
9,424 |
8,339 |
$12K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
7,450 |
6,035 |
$11K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,069 |
1,045 |
$11K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
581 |
565 |
$10K |
| 84443 |
Thyroid stimulating hormone (TSH) |
6,143 |
6,001 |
$10K |
| 82950 |
|
1,196 |
1,184 |
$9K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,474 |
1,460 |
$8K |
| 73090 |
|
135 |
131 |
$8K |
| 73080 |
|
127 |
124 |
$8K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
5,678 |
4,683 |
$7K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
956 |
948 |
$7K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
5,728 |
4,968 |
$7K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
1,255 |
753 |
$7K |
| 96376 |
|
2,020 |
1,402 |
$7K |
| 86780 |
|
1,464 |
1,398 |
$7K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,470 |
2,374 |
$7K |
| 80076 |
|
1,669 |
1,500 |
$7K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
528 |
525 |
$6K |
| 76770 |
|
73 |
72 |
$6K |
| 84439 |
|
1,031 |
1,005 |
$5K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,931 |
2,879 |
$5K |
| G0378 |
Hospital observation service, per hour |
1,675 |
1,428 |
$4K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
786 |
755 |
$4K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
917 |
543 |
$4K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
89 |
89 |
$4K |
| 73502 |
|
175 |
170 |
$4K |
| 82607 |
|
730 |
719 |
$4K |
| 82728 |
|
558 |
542 |
$4K |
| 82105 |
|
283 |
274 |
$3K |
| 83735 |
|
4,595 |
3,570 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
6,754 |
5,659 |
$3K |
| 96367 |
|
144 |
123 |
$3K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
5,811 |
5,394 |
$3K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
106 |
84 |
$3K |
| 84484 |
|
6,542 |
4,859 |
$3K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
18 |
18 |
$3K |
| 93970 |
|
12 |
12 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
6,866 |
6,009 |
$2K |
| 93017 |
|
40 |
38 |
$2K |
| 82043 |
|
294 |
293 |
$2K |
| 87807 |
|
82 |
82 |
$2K |
| 73140 |
|
26 |
26 |
$2K |
| 83605 |
|
2,867 |
2,357 |
$2K |
| 76536 |
|
13 |
13 |
$2K |
| J3490 |
Unclassified drugs |
5,724 |
2,904 |
$2K |
| 74022 |
|
109 |
105 |
$2K |
| 85379 |
|
1,473 |
1,422 |
$1K |
| 73590 |
|
85 |
79 |
$1K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
97 |
90 |
$1K |
| 87205 |
|
757 |
700 |
$1K |
| 93976 |
|
1,136 |
1,092 |
$1K |
| 82550 |
|
560 |
495 |
$1K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
868 |
768 |
$1K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
333 |
250 |
$1K |
| 85027 |
|
2,666 |
2,454 |
$1K |
| 88304 |
|
38 |
38 |
$1K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
1,996 |
1,676 |
$1K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
190 |
176 |
$1K |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
837 |
722 |
$1K |
| 85014 |
|
117 |
100 |
$987.32 |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
12 |
12 |
$958.92 |
| 87186 |
|
2,793 |
2,651 |
$883.59 |
| 12001 |
|
14 |
14 |
$812.00 |
| 82570 |
|
418 |
376 |
$805.19 |
| 86803 |
|
495 |
492 |
$706.47 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,172 |
1,999 |
$650.75 |
| J2060 |
Injection, lorazepam, 2 mg |
277 |
217 |
$646.98 |
| 86140 |
|
1,926 |
1,775 |
$621.15 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
13 |
13 |
$516.86 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
636 |
551 |
$507.81 |
| 80074 |
|
12 |
12 |
$506.84 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,285 |
1,917 |
$504.65 |
| 76775 |
|
14 |
14 |
$493.36 |
| 83880 |
|
1,962 |
1,792 |
$446.41 |
| 84156 |
|
83 |
73 |
$442.00 |
| 85007 |
|
598 |
532 |
$423.17 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
4,030 |
3,159 |
$354.50 |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
148 |
142 |
$343.10 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
604 |
203 |
$329.85 |
| 86592 |
|
45 |
37 |
$317.92 |
| 84145 |
|
991 |
901 |
$280.11 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
370 |
317 |
$243.51 |
| 76942 |
|
60 |
59 |
$236.45 |
| 82247 |
|
133 |
61 |
$223.94 |
| 82140 |
|
27 |
24 |
$220.82 |
| 82040 |
|
39 |
26 |
$190.84 |
| 85018 |
|
795 |
745 |
$164.03 |
| 84146 |
|
27 |
25 |
$163.36 |
| 86762 |
|
886 |
828 |
$124.91 |
| 85610 |
|
2,255 |
2,023 |
$121.10 |
| 83540 |
|
427 |
422 |
$113.65 |
| J1815 |
Injection, insulin, per 5 units |
700 |
326 |
$82.79 |
| 83690 |
|
5,820 |
5,362 |
$72.25 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,003 |
978 |
$64.12 |
| 90715 |
|
250 |
242 |
$33.90 |
| 85651 |
|
651 |
612 |
$24.95 |
| 97162 |
|
157 |
146 |
$24.81 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
1,662 |
1,488 |
$20.88 |
| 84132 |
|
12 |
12 |
$16.31 |
| 84550 |
|
26 |
25 |
$14.45 |
| 82077 |
|
1,357 |
1,254 |
$13.82 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,737 |
2,163 |
$2.38 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,861 |
1,592 |
$1.26 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
788 |
718 |
$0.47 |
| 86901 |
|
2,105 |
1,945 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
576 |
427 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,300 |
3,086 |
$0.00 |
| 85730 |
|
1,033 |
963 |
$0.00 |
| 87340 |
|
1,091 |
1,026 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
506 |
478 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,136 |
1,755 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
72 |
69 |
$0.00 |
| 85652 |
|
536 |
504 |
$0.00 |
| 82677 |
|
32 |
28 |
$0.00 |
| 87040 |
|
1,402 |
943 |
$0.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
83 |
77 |
$0.00 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
234 |
225 |
$0.00 |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
13 |
12 |
$0.00 |
| 90870 |
|
37 |
12 |
$0.00 |
| 82746 |
|
25 |
25 |
$0.00 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
13 |
13 |
$0.00 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
39 |
39 |
$0.00 |
| 86580 |
|
45 |
39 |
$0.00 |
| 70498 |
|
25 |
25 |
$0.00 |
| 76801 |
|
44 |
40 |
$0.00 |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
18 |
15 |
$0.00 |
| 94761 |
|
18 |
12 |
$0.00 |
| 70496 |
|
13 |
13 |
$0.00 |
| 82803 |
|
13 |
13 |
$0.00 |
| 84100 |
|
1,323 |
956 |
$0.00 |
| 80143 |
|
494 |
454 |
$0.00 |
| 80179 |
|
410 |
376 |
$0.00 |
| 86336 |
|
32 |
28 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
1,336 |
635 |
$0.00 |
| 76000 |
|
100 |
98 |
$0.00 |
| 82805 |
|
178 |
144 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
150 |
146 |
$0.00 |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
14 |
14 |
$0.00 |
| 84466 |
|
411 |
406 |
$0.00 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
22 |
12 |
$0.00 |
| 82248 |
|
163 |
95 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
151 |
141 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
154 |
144 |
$0.00 |
| 97116 |
|
89 |
36 |
$0.00 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
148 |
145 |
$0.00 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
16 |
16 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
32 |
31 |
$0.00 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
20 |
15 |
$0.00 |
| 84403 |
|
13 |
12 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
203 |
167 |
$0.00 |
| 86038 |
|
13 |
13 |
$0.00 |
| 36600 |
|
31 |
26 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
52 |
40 |
$0.00 |
| 51701 |
|
13 |
12 |
$0.00 |